Abstract: PURPOSE: To explore the clinical efficacy and safety of betaxolol hydrochloride eye drops treatment for superficial infantile hemangiomas. METHODS: Among 31 cases with superficial infantile hemangiomas, 7 patients (3 males and 4 females) with superficial infantile hemangiomas were selected　according to inclusion criteria, their age ranged from 30 days to 156 days, with an average age of 97 days. Betaxolol hydrochloride eye drops were applied on the tumor surface, 5 times per day in children older than 2 months, and 3 times per day in children less than 2 months. The changes of color, size, tension and thickness were recorded before and after treatment, and adverse reactions were observed in order to evaluate the safety of the treatment. RESULTS: After treatment, 7 patients had varying degrees of reduction and softened texture, the lesion color faded, no adverse reactions were noted. CONCLUSIONS: Betaxolol hydrochloride eye drops might be one of the effective ways to treat superficial infantile hemangiomas with less adverse reaction.

Key words: Infantile ｈemangiomas, Betaxolol hydrochloride eye drops, β-adrenergic receptor blocker